Laryngeal Dysfunction in Acute Organophosphorus and Carbamate Poisoning

Gajalakshmi S Mani1, Suma S Mathews2, Punitha Victor3, John V Peter4, Bijesh Yadav5, Rita RA Albert6

ABSTRACT

Background: Organophosphorus (OP) and carbamate pesticides are widely used for crop protection. We describe the spectrum of laryngeal abnormalities in patients admitted to the intensive care unit (ICU) with acute OP and carbamate poisoning as there is limited information on it.

Materials and methods: Consecutive patients admitted to the ICU with acute OP and carbamate poisoning over 20 months (December 2014–July 2016) were recruited. Patients were followed up post-discharge if they had undergone tracheostomy or developed hoarseness of voice or stridor following extubation. Asymptomatic individuals who consented underwent laryngoscopy after ICU discharge. The primary outcome was the development of laryngeal dysfunction. Other outcomes included length of stay, need for ventilation, mortality, tracheostomy, and time to decannulation of tracheostomy.

Results: Of the 136 patients recruited, 71 (52%) underwent laryngoscopy. The overall mortality rate was 9.6%. Of the 71 patients who underwent laryngoscopy, 18 had abnormal findings, which included unilateral or bilateral vocal cord paresis or palsy (n = 14) and/or aspiration (n = 9), subglottic stenosis (n = 1), tracheal stenosis (n = 1), or arytenoid granuloma (n = 1). Laryngeal dysfunction was associated with the ingestion of a dimethyl OP compound (p = 0.04) and quantum consumed (p < 0.001). Patients with laryngeal dysfunction had significantly (p = 0.004) longer hospital stay (19.1 ± 10.7 vs 11.8 ± 8.3 days).

Conclusion: Laryngeal dysfunction is not uncommon in OP and carbamate poisoning and is associated with the ingestion of larger quantity of a dimethyl OP compound and longer hospital stay. Otorhinolaryngologists could be involved early to help identify these abnormalities and initiate an appropriate treatment to ensure a functional voice and good airway.

Keywords: Aspiration, Organophosphorus poisoning, Poisoning, Subglottic stenosis, Vocal cord paralysis.

Indian Journal of Critical Care Medicine (2022): 10.5005/jp-journals-10071-24096

INTRODUCTION

Deliberate ingestion of pesticide is a leading cause of suicide in India. Among the commonly used pesticides, poisoning with organophosphorus (OP) compounds and carbamates is frequent because of easy availability. The incidence is high in India and more so in Tamil Nadu.1

Three distinct patterns of neuromuscular weakness are described: acute weakness (type I paralysis), which occurs within a few minutes to few hours after exposure; intermediate syndrome (type II paralysis), which generally occurs after 24 hours and lasts up to 1–2 weeks; and organophosphate-induced delayed polyneuropathy (OPIDP) (type III paralysis), which occurs after several weeks following exposure.2,3 Type I weakness is due to cholinergic overstimulation, type II weakness is due to neuromuscular dysfunction, and type III paralysis is a result of covalent inhibition of the neuropathy target esterase (NTE).3,4

There are several case reports5–9 and one small case series10 that describes laryngeal dysfunction in the setting of OP poisoning. This has been observed not only in type II paralysis6 or failed extubation7 but also as a late manifestation with delayed-onset laryngeal dysfunction.6,10

In one report, laryngeal electromyography (EMG) ruled out cricoarytenoid joint injury or arytenoids dislocation and confirmed bilateral laryngeal paralysis.5 Given the paucity of the literature on the topic, this study was undertaken to describe the laryngeal abnormalities in OP poisoning and the factors associated with its occurrence.

© The Author(s), 2022 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

MATERIALS AND METHODS

This cohort study was conducted in the medical intensive care unit (ICU) of a tertiary care university-affiliated teaching hospital in South India over 20 months (December 2014–July 2016). Patients who presented following deliberate ingestion of an OP compound or carbamate were included. The diagnosis of OP or carbamate poisoning was made based on the container brought by the patient in the setting of clinical signs of OP/carbamate poisoning.
poisoning in combination with reduced pseudocholinesterase activity (reference range 3000–8000 IU/L). Patients with unknown poisoning were also included if they manifested cholinergic signs and had evidence of cholinesterase suppression. Nonconsenting patients, those with preexisting laryngeal pathology, pregnant women, mentally challenged individuals, and those with a previous admission requiring ventilatory support were excluded.

Patients were managed using standard protocols for the management of OP poisoning that included atropine and supportive therapy for organ dysfunction. Patients with hypotension (systolic blood pressure <90 mm Hg) were fluid resuscitated. If they continued to be hypotensive despite adequate fluid resuscitation, they were started on an appropriate vasoactive agent, based on the clinical assessment of the etiology of shock. Patients with respiratory failure were managed with noninvasive or invasive ventilation as appropriate. Patients who were invasively ventilated received analgo-sedation as a combination of morphine or fentanyl along with midazolam. Endotracheal or tracheostomy tubes with high-volume, low-pressure cuffs were used with protocolized periodic check of the cuff pressure to ensure that cuff pressures did not exceed 30 cm water. Sedation was ceased prior to extubation.

All patients were assessed for readiness for extubation using a combination of factors that included the assessment of (a) airway (using cuff leak and cough test), (b) adequacy of breathing (ensuring a reasonable respiratory rate on minimal ventilatory supports and a forced vital capacity (FVC) of at least 15 mL/kg), (c) stable hemodynamics (on minimal or no inotropes), (d) normal electrolytes (potassium and phosphorus), and (e) a Glasgow Coma Scale of at least 77/10 and no evidence of significant proximal or neck muscle weakness. In the setting of OP poisoning, given our experience that neuromuscular weakness could fluctuate in a span of few hours, at least two assessments of muscle function (proximal and neck muscle) and FVC were done (minimum 6 hours apart) prior to extubation. Where there was still an element of doubt on ventilatory reserve, a T-piece trial was given for a period of not exceeding 1–2 hours prior to extubation.

Patients who failed extubation were trialed on noninvasive ventilation or re-intubated depending on the clinical situation. The cause for failed extubation was assessed as to whether it was due to airway-related issues or ventilatory failure/fatigue. Post re-intubation, if the cause was ascertained to be due to an airway problem (e.g., laryngeal dysfunction), a surgical tracheostomy was performed by the otolaryngologist either in the ICU at the bedside or in the operating theater if there was a perceived higher risk of complications. Percutaneous tracheostomy was not considered in this setting. If the reason for failed extubation was ventilatory fatigue, the patient was reassessed after a further period of ventilatory support for readiness for extubation. In the absence of airway compromise, if ventilatory failure persisted, then tracheostomy was done during the second week of ICU admission. Patients who underwent tracheostomy for airway compromise were quickly weaned to a T-piece, with respiratory muscle weakness improved. Once weaned, the patient was transferred from the ICU to the ward for further care. Decannulation of the tracheostomy was done either during hospital stay or after discharge in the outpatient clinic after ensuring that vocal cord function had improved and airway was adequate.

Patients underwent flexible laryngoscopy during hospitalization if they developed hoarseness of voice or stridor following extubation or if they required tracheostomy. Findings of vocal cord paresis or paralysis, aspiration, laryngotracheal stenosis, and granuloma formation were recorded. These patients were advised review in the outpatient clinic for the reassessment of vocal cord function as well as decannulation of tracheostomy if this was not done prior to hospital discharge. Hospital records were reviewed to obtain longer follow-up data, where available. Other patients with severe OP poisoning who did not manifest symptoms of airway compromise were also approached for their willingness to undergo flexible laryngoscopy post ICU discharge.

Cases were defined as patients who developed evidence of laryngeal dysfunction during the course of ICU admission or immediately post ICU discharge. Laryngeal dysfunction was diagnosed if there was direct evidence of vocal cord dysfunction (e.g., vocal cord paresis or paralysis) or indirect evidence of vocal cord dysfunction without overt evidence of cord paresis (e.g., aspiration). Aspiration was defined as entry of secretions past the vocal folds, as evidenced on laryngoscopy. Follow-up laryngoscopy was done to assess the cord mobility as well as sequelae such as granuloma formation or stenosis.

Demographic, treatment, and outcome data of patients who underwent laryngoscopy during the study period were recorded prospectively. Data of all other patients who were admitted with OP/carbamate poisoning during the study period but did not undergo laryngoscopy were obtained post hoc from hospital records. The primary outcome of interest was the development of laryngeal dysfunction, which included vocal cord paresis or paralysis, aspiration, stenosis, and granuloma formation. Secondary outcomes included mortality, length of stay, need for ventilation, tracheostomy, and time to decannulation of tracheostomy.

Statistical Analysis

Baseline characteristics were summarized as frequencies (percentages) for categorical variables as mean (standard deviation, SD) or median (interquartile range, IQR) for continuous variables as appropriate. Mann–Whitney U-test or Fisher’s exact test was used to compare the characteristics of patients who underwent laryngoscopy with those who did not undergo laryngoscopy as well as those who had laryngeal dysfunction and those who did not develop laryngeal dysfunction. All statistical analyses were done using STATA v15.0 (StataCorp, College Station, Texas). The study was approved by the Institutional Review Board and the Ethics Committee of the hospital (IRB No: 9142/2014).

Results

The study cohort of 136 patients (90 males and 46 females) comprised a relatively young population, with a mean ± SD age of 31.3 ± 12.8 years and moderate severity of illness. Diethyl (41.2%) and dimethyl (29.4%) OP were the main compounds ingested. Nearly 90% of patients required ventilation and 24.3% required tracheostomy. The overall in-hospital mortality rate was 9.6%.

When the characteristics of patients who underwent laryngoscopy (n = 71) were compared with those who did not (n = 65), patients who did not have laryngoscopy were sicker (p = 0.005) and had higher mortality (Table 1). On the other hand, duration of ventilation, need for tracheostomy, and length of stay were significantly higher in the group that underwent laryngoscopy (Table 1).

Of the 71 patients who underwent flexible laryngoscopy, 62 (87.3%) were intubated and 9 (12.7%) were not intubated...
Laryngeal Dysfunction in Poisoning

Table 1: Baseline characteristics and outcomes of the entire study cohort

|                          | All patients (n = 136) | Laryngoscopy done (n = 71) | No laryngoscopy (n = 65) | p value |
|--------------------------|------------------------|-----------------------------|--------------------------|---------|
| Age, years               | 31.3 (12.8)            | 29.6 (10.6)                 | 33.1 (14.6)              | 0.12    |
| Gender, Male:Female      | 90:46                  | 49:22                       | 41:24                    | 0.48    |
| APACHE II score          | 13.0 (6.2)             | 11.3 (5.2)                  | 14.6 (7.0)               | 0.005   |
| Type of compound         |                        |                             |                          |         |
| Dimethyl                 | 40 (29.4)              | 21 (29.6)                   | 19 (29.7)                | 0.89    |
| Diethyl                  | 56 (41.2)              | 31 (43.7)                   | 24 (37.5)                |         |
| S-alkyl                  | 7 (5.2)                | 3 (4.2)                     | 4 (6.3)                  |         |
| Carbamate                | 3 (2.2)                | 1 (1.4)                     | 2 (3.1)                  |         |
| Unknown                  | 30 (22.0)              | 15 (21.1)                   | 15 (23.4)                |         |
| Amount ingested, mL      | 86.7 (72.9)            | 77.4 (47.3)                 | 105.2 (106)              | 0.09    |
| Cholinesterase, U/L †    | 122 (89–308)           | 130 (90–334)                | 115 (85–297)             | 0.59    |
| Number ventilated        | 121 (89)               | 62 (87.3)                   | 59 (90.8)                | 0.59    |
| Ventilation duration, days | 7.5 (5.9)            | 9.3 (7.0)                   | 5.5 (3.6)                | 0.0003  |
| VFD, days                | 18.4 (8.4)             | 18.8 (6.6)                  | 17.9 (10.0)              | 0.54    |
| Number tracheostomy      | 33/121 (27.3)          | 29/62 (46.8)                | 4/59 (6.8)†              | <0.001  |
| Day of tracheostomy      | 7.8 (3.6)              | 7.7 (3.4)                   | 8.5 (3.4)                | 0.67    |
| Day of decannulation; Median (IQR) days‡ | 31 (20.8–47.5) | 32 (19.5–48)                | 30—                     |         |
| Length of hospital stay, days | 11.2 (8.3)           | 13.7 (9.5)                  | 8.6 (5.7)                | 0.003   |
| Mortality*               | 13 (9.6)               | 0 (0)                       | 13 (20)                  | <0.001  |

All values are mean (standard deviation) unless specified; APACHE, acute physiology and chronic health evaluation; †Median (interquartile range, IQR) pseudocholinesterase; *For these variables, values are the number of patients and the percentages are in parentheses; VFD, ventilator-free days, calculated as (28 – duration of ventilation)—ventilator free days is zero for those who died; ‡Three of these patients either died or were discharged against medical advice; *Of the four patients who underwent tracheostomy in those who did not undergo laryngoscopy, three patients died, hence, the day of decannulation is available in the only survivor.

Flowchart 1: Flow diagram of patients recruited to the study

(Flowchart 1). Twenty-nine patients (46.8%) required tracheostomy, of whom 11 (37.9%) had laryngeal dysfunction. In the subset of patients who were intubated and did not undergo tracheostomy, six (18.2%) had evidence of laryngeal dysfunction (Flowchart 1). Among those who were not intubated and consented for laryngoscopy (n = 9), one (11.1%) had laryngeal dysfunction.

Table 2 compares the baseline characteristics and outcomes of patients who had evidence of laryngeal dysfunction (n = 18) with those of patients who had a normal study (n = 53). The quantum of poison consumed and the ingestion of a dimethyl compound were significantly associated with laryngeal dysfunction (Table 2). Patients who developed laryngeal dysfunction had more attempts at intubation (p = 0.02), failed extubation (p = 0.05), requirement for tracheostomy (p = 0.04), and stayed longer in hospital (19.1 ± 10.7 vs 11.8 ± 8.3 days; p = 0.004) when compared with those who had no evidence of laryngeal dysfunction.

Table 3 provides clinical details of the 18 patients who developed laryngeal dysfunction. Of note, during the first
Laryngeal Dysfunction in Poisoning

Table 2: Baseline characteristics and outcomes of those who underwent flexible laryngoscopy

|                                | All patients (n = 71) | Abnormal laryngoscopy (n = 18) | Normal laryngoscopy (n = 53) | p value |
|--------------------------------|-----------------------|-------------------------------|------------------------------|---------|
| Age                            | 29.6 (10.6)           | 28.7 (11.6)                   | 29.9 (10.3)                  | 0.68    |
| Gender, Male:Female             | 49:22                 | 11:7                         | 38:15                        | 0.40    |
| APACHE II score                 | 11.3 (5.2)            | 11.1 (3.1)                    | 11.4 (5.9)                   | 0.87    |
| Type of compound               |                       |                               |                              |         |
| Dimethyl                       | 21 (29.6)             | 9 (50.0)                      | 12 (22.6)                    | 0.04    |
| Diethyl                        | 31 (43.7)             | 6 (33.3)                      | 25 (47.2)                    |         |
| S-alkyl                        | 3 (4.2)               | 1 (5.6)                       | 2 (3.8)                      |         |
| Carbamate                      | 1 (1.4)               | 1 (5.6)                       | 0 (0)                        |         |
| Unknown                        | 15 (21.1)             | 1 (5.6)                       | 14 (26.4)                    |         |
| Amount ingested, mL            | 77.4 (47.3)           | 127.9 (68.9)                  | 64.8 (29.6)                  | <0.001* |
| Cholinesterase, U/L            | 130 (90–334)          | 130 (90–171)                  | 127 (92–368)                 | 0.73    |
| Intubation >1 attempt           | 6/54 (11.1)†          | 3/9 (33)                      | 3/45 (6.7)                   | 0.02    |
| Number ventilated              | 62 (87.3)             | 17 (94.4)                     | 45 (84.9)                    | 0.43    |
| Ventilation duration, days     | 9.3 (7.0)             | 11.4 (5.5)                    | 8.5 (7.4)                    | 0.16    |
| VFD, days                      | 18.8 (6.6)            | 16.7 (5.5)                    | 19.7 (6.8)                   | 0.11    |
| Failed extubation              | 12/62‡                | 6/12 (50)                     | 6/5 (22)                     | 0.05‡   |
| Number tracheostomy            | 29 (40.9)             | 11 (61.1)                     | 18 (34.0)                    | 0.04‡   |
| Day of tracheostomy            | 7.7 (3.4)             | 8.9 (2.5)                     | 7.0 (3.7)                    | 0.15    |
| Day of decannulation           | 37 (22.8)             | 28.6 (23.4)                   | 41.7 (21.6)                  | 0.14    |
| Length of hospital stay, days  | 13.7 (9.5)            | 19.1 (10.7)                   | 11.8 (8.3)                   | 0.004‡  |
| Mortality                      | 0 (0)                 | 0 (0)                         | 0 (0)                        | —       |

All values are mean (standard deviation) unless specified; APACHE, acute physiology and chronic health evaluation; IQR, interquartile range. For these variables, values are the number of patients and the percentages are in parentheses; VFD, ventilator-free days, calculated as (28 – duration of ventilation) — ventilator-free days is zero for those who died; † Significant value; ‡ Data available only in 54 patients for intubation attempts and for 62 patients for failed extubation.

The laryngeal dysfunction examination which was done at a median time of 17.5 days (IQR 14.5–24), direct visual evidence of vocal cord dysfunction (unilateral or bilateral vocal cord paresis or palsy) was observed in 14 patients, while 8 patients had evidence of aspiration, with or without vocal cord dysfunction. Four patients had only evidence of aspiration without any overt vocal cord paresis. During the subsequent follow-up laryngoscopy which was done at a median time of 45.5 days (IQR 31–53), one patient each had subglottic narrowing, arytenoid granuloma, and tracheal stenosis and an additional patient had evidence of aspiration. All patients had evidence of vocal cord dysfunction within 4 weeks of poisoning, and 11 patients (61.1%) required tracheostomy. One-third of the patients (6/18) who had evidence of laryngeal dysfunction were lost to follow up. It was interesting to note that one patient who had subglottic narrowing (grade I) had not been intubated; since the airway was adequate, no surgical intervention was required. Another patient who was initially noted to have left vocal cord palsy presented 6 weeks later with stridor. While the vocal cord palsy had recovered, the patient had developed tracheal stenosis. This patient underwent tracheal resection and anastomosis and on follow-up continues to have a good airway.

**Discussion**

In this cohort study of 136 patients admitted to the ICU with OP or carbamate poisoning, 71 patients (52%) underwent flexible laryngoscopy. In the initial evaluation, 18 patients had evidence of laryngeal dysfunction that included unilateral or bilateral vocal cord immobility and/or aspiration. Delayed complications of intubation that were observed in this series included laryngotracheal stenosis and vocal granuloma. Laryngeal dysfunction was significantly associated with the ingestion of a dimethyl OP compound, quantum ingested, multiple intubation attempts, failed extubation, need for tracheostomy, and longer hospital stay.

Although there are case reports of laryngeal dysfunction in OP poisoning, this study is a descriptive study of the laryngeal dysfunction in a cohort of patients admitted to the ICU with OP or carbamate poisoning. The estimated incidence of laryngeal dysfunction in this cohort of 25.4% is likely to be overestimated or underestimated and hence not reported due to the following reasons. The cohort comprised only patients admitted to the ICU and did not include all patients admitted to the wards with less severe manifestations; only about half underwent laryngoscopy. These introduce a selection bias. Further higher illness severity and mortality in those who did not undergo laryngoscopy could have also altered the incidence of laryngeal dysfunction (Table 1).

It is likely that several factors contribute to laryngeal dysfunction in this setting. The association between the quantum of poison ingested and the type of poison (dimethyl OP) and the development of laryngeal dysfunction is not surprising. Further, analysis was precluded by the fact that 11 different compounds were associated with laryngeal dysfunction (Table 3). Monocrotophos (n = 3), dimethoate (n = 3), chlorpyrifos (n = 2), and phorate (n = 2) were the main compounds implicated in our study. In the published reports, several compounds were implicated and no compound was implicated twice in laryngeal dysfunction.

The observation of an association between failed extubation and need for tracheostomy and laryngeal dysfunction is also not surprising since extubation failure occurred in these patients despite careful assessment of readiness for extubation through a protocolized checklist. The need for tracheostomy and the delay in decannulation (Table 3) due to vocal cord dysfunction...
Laryngeal Dysfunction in Poisoning

The mechanism of laryngeal weakness is unclear. It is likely that laryngeal weakness is due to the same pathophysiological mechanisms that result in proximal and neck muscles in intermediate syndrome. In one study where laryngeal EMG was performed, widespread fibrillation and positive sharp waves were observed in the muscles innervated by the recurrent laryngeal nerve. There was also a significant reduction in voluntary motor unit action potential during attempts at muscle contraction in the cricothyroid muscles innervated by the external branch of the superior laryngeal nerve. On the other hand, the mechanism of delayed-onset laryngeal dysfunction in the previously published case series is probably different and related to the pathophysiology of OPIDP, wherein the inhibition of the NTE is the likely mechanism for weakness, since this occurred several days after extubation. The aspiration seen in about 50% of the subjects could be due to the superior laryngeal nerve dysfunction, the subtle findings which can easily be missed in another could be related to post-intubation-induced mucosal injury. The tracheal stenosis seen in one patient and the arytenoid granuloma in another could be related to post-intubation-induced mucosal injury. The inflammation and scarring in the airway due to mucosal ischemia (decreased capillary perfusion secondary to cuff pressure) could have also been aggravated by hypotension, acid reflux, and

Table 3: Clinical details and follow-up data of patients with laryngeal abnormalities

| No | Age/sex | Compound | Type of OP | Amt. ingested | Vent | Vent durn | Trach | Trach day | Day decan | Initial laryngoscopy (day) | Final laryngoscopy (day) |
|----|---------|----------|------------|---------------|------|----------|------|----------|----------|-----------------------------|---------------------------|
| 1  | 18/M    | Dichlorvos | Dimethyl   | 100 mL        | Yes  | 3        | No   | —        | —        | Left VC palsy (5)           | Left VC palsy (NA)        |
| 2  | 24/F    | Carbofuran | Carbamate  | 40 mL         | No   | —        | —    | —        | —        | Left VC palsy (NA)          | Subglottic stenosis grade I (NA) |
| 3  | 16/F    | Phorate   | Diethyl    | 80 mL         | Yes  | 8        | No   | —        | —        | Left VC palsy (16)          | Left VC palsy (NA)        |
| 4  | 50/M    | Dimethoate | Dimethyl   | 250 mL        | Yes  | 10       | No   | —        | —        | Left VC palsy (30)          | Normal (47)               |
| 5  | 45/M    | Malathion | Dimethyl   | 200 mL        | Yes  | 8        | Yes  | 5        | 17       | Aspiration (16)             | Normal (21)               |
| 6  | 55/M    | Malathion | Dimethyl   | 80 mL         | Yes  | 11       | Yes  | 6        | 92       | Left VC palsy (15)          | Left VC palsy (58)        |
| 7  | 19/M    | Unknown   | —          | 100 mL        | Yes  | 11       | Yes  | 9        | 30       | Left VC palsy (18)          | Left VC palsy (53)        |
| 8  | 23/F    | Chlorpyrifos | Diethyl   | 150 mL        | Yes  | 17       | Yes  | 7        | 36       | Bilateral VC palsy (20)     | Bilateral vocal paresis (42) |
| 9  | 33/M    | Phorate   | Diethyl    | 200 mL        | Yes  | 12       | Yes  | 11       | 13       | Aspiration (NA)             | Aspiration (NA)           |
| 10 | 20/F    | Monocrotophos | Dimethyl | NA            | Yes  | 4        | Yes  | 8        | 32       | Aspiration (17)             | Aspiration (31)           |
| 11 | 35/M    | Quinalphos | Diethyl    | 75 mL         | Yes  | 18       | Yes  | 9        | 32       | Bilateral VC paresis (25)   | Left VC paresis (53)       |
| 12 | 27/M    | Triazophos | Diethyl    | NA            | Yes  | 22       | Yes  | 14       | 30       | Aspiration (24)             | Normal (27)               |
| 13 | 18/F    | Prophenofos | S-alkyl  | 250 mL        | Yes  | 14       | Yes  | 10       | 8        | Left VC palsy (24)          | Lost to follow up          |
| 14 | 36/F    | Chlorpyrifos | Diethyl  | NA            | Yes  | 19       | Yes  | 10       | 8        | Bilateral VC palsy (25)     | Left VC paresis (44)       |
| 15 | 28/M    | Monocrotophos | Dimethyl | NA            | Yes  | 14       | Yes  | 9        | 17       | Aspiration (22)             | Normal (57)               |
| 16 | 28/M    | Dimethoate | Dimethyl   | NA            | Yes  | 11       | No   | —        | —        | Left VC paresis (14)        | Lost to follow up          |
| 17 | 25/M    | Monocrotophos | Dimethyl | 200 mL        | Yes  | 5        | No   | —        | —        | Left VC palsy (11)          | Normal mobile cords        |
| 18 | 17/F    | Phosphenetoin | Dimethyl | NA            | Yes  | 6        | No   | —        | —        | Left VC palsy (12)          | Lost to follow up          |

OP: organophosphorus; Amt: amount; Vent: ventilation; durn: duration; Trach: tracheostomy; decan: decannulation; VC: vocal cord; NA: not available; day in parentheses describe the day following hospital admission when laryngoscopy was done; NA: data not available

support the hypothesis that vocal cord dysfunction in this setting takes time to resolve. These observations are consistent with the published literature. In two reports, failed extubation was due to bilateral vocal cord paralysis. In another report, the patient developed hoarseness post-extubation that progressed to life-threatening stridor. The time to resolution of vocal cord function was 2 weeks to 2 months in these reports, consistent with our observations. The case series of three patients who developed delayed laryngeal symptoms contrasts our cohort; in this series, laryngeal dysfunction occurred 14–26 days after extubation and lasted 4–15 weeks.

One confounding factor needs to be addressed. It is likely that multiple attempts at intubation, particularly by inexperienced trainees, could also result in laryngeal trauma, edema, and failed extubation. Although multiple intubation attempts were associated with laryngeal dysfunction in our study (p = 0.02), it was not clear if they were causal for laryngeal dysfunction. Laryngeal edema, trauma, or dislocation of arytenoid cartilage was not observed on flexible laryngoscopy in our patients. Given that laryngeal dysfunction occurred even in un-intubated patients (1/9; 11.1%), it is likely that OP compounds can directly cause laryngeal weakness.
To be noted is the fact that one patient with subglottic narrowing was not intubated.

The following limitations merit mention. This was a single-center study focused only on critically ill OP-poisoned patients. It would have been ideal to answer the association between OP poisoning and laryngeal dysfunction using a case–control study; however, this was planned as a cohort study. Although the plan was to recruit consecutive patients, several patients (around 50%) could not be recruited due to the nonavailability of the principle investigator during weekends or leave as well as the treating clinician’s decision to not subject patient to laryngoscopy. Although this problem was circumvented to some extent by the inclusion of the entire cohort of patients admitted to the ICU during the study period through post hoc review of the hospital records, this introduced a selection bias in determining the incidence of laryngeal dysfunction. Hence, we opted to not provide an estimate of the incidence of laryngeal dysfunction as this would have either overestimated or underestimated the incidence. The study was thus restricted to describe the nature of laryngeal dysfunction as a basis for further work using the appropriate study design.

Besides association between the quantum of poison ingested and the type of poison (dimethyl OP), further subgroup analysis was precluded by the fact that 11 different compounds were associated with laryngeal dysfunction (Table 4). Only about 50% of patients were assessed for laryngeal dysfunction. Laryngeal EMG was not done in our study. This would have helped delineate those with cord dysfunction due to the pesticide from arytenoid dislocation due to traumatic endotracheal intubation. Further unmeasured/unknown factors (e.g., solvents) could have also contributed to laryngeal dysfunction. A subset of patients with laryngeal dysfunction were lost to follow up, and hence, recovery of vocal cord function could not be documented in all. Despite these limitations, this study provides a detailed description of the nature of laryngeal dysfunction and the course in these patients.

**CONCLUSION**

A functional voice and good airway is vital, particularly in patients who recover from critical illness and return to their homes to make a living. The laryngeal dysfunction noted in those with nonfatal suicidal attempts may be either due to OP neurotoxicity or mechanical trauma due to laryngotracheal intubation. This warrants further study focusing on delineating the mechanisms through detailed EMG studies and extended follow-up periods. The otolaryngologist could facilitate the detection of laryngeal abnormalities and initiate suitable care to ensure a functional voice and an adequate airway.

**Orcid**

Gojralakshmi S Mani https://orcid.org/0000-0002-7594-5071
Suma S Mathews https://orcid.org/0000-0001-5573-2610
Punitha Victor https://orcid.org/0000-0002-3978-7272
John V Peter https://orcid.org/0000-0002-3423-1830
Bijesh Yadav https://orcid.org/0000-0002-5764-1373
Rita RA Albert https://orcid.org/0000-0001-5450-5205

**References**

1. Prasad J, Abraham VJ, Minz S, Abraham S, Joseph A, Muliyil JP, et al. Rates and factors associated with suicide in Kaniyambadi Block, Tamil Nadu, South India, 2000–2002. Int J Soc Psychiatry 2006;52(1):65–71. DOI: 10.1177/0020764006061253.
2. Singh S, Sharma N. Neurological syndromes following organophosphate poisoning. Neurol India 2000;48(4):308–313. PMID: 11146591.
3. Peter JV, Sudarsan TI, Moran JL. Clinical features of organophosphate poisoning: a review of different classification systems and approaches. Indian J Crit Care Med 2014;18(11):735–745. DOI: 10.4103/0972-5229.144017.

4. Singh G, Khurana D. Neurology of acute organophosphate poisoning. Neurol India 2009;57(2):119–125. DOI: 10.4103/0028-3886.51277.

5. Moretto A, Lotti M. Poisoning by organophosphorus insecticides and sensory neuropathy. J Neurol Neurosurg Psychiatry 1998;64(4):463–468. DOI: 10.1136/jnnp.64.4.463.

6. Jin Y-H, Jeong T-O, Lee J-B. Isolated bilateral vocal cord paralysis with intermediate syndrome after organophosphate poisoning. Clin Toxicol (Phila) 2008;46(5):482–484. DOI: 10.1080/15563650701704842.

7. Indudharan R, Win MN, Noor AR. Laryngeal paralysis in organophosphorous poisoning. J Laryngol Otol 1998;112(1):81–82. DOI: 10.1017/s0022215100139969.

8. Vaidya SR, Salvi MM, Karnik ND, Sunder U, Yeolekar ME. Life threatening stridor due to bilateral recurrent laryngeal nerve palsy as an isolated manifestation of intermediate syndrome. J Assoc Physicians India 2002;50:454–455. PMID: 11922245.

9. Shetye JV, Surkar SM, Karnik ND, Mehta AA. Delayed onset neuropathy along with recurrent laryngeal nerve palsy due to organophosphate poisoning and the role of physiotherapy rehabilitation. Indian J Crit Care Med 2014;18(2):102–104. DOI: 10.4103/0972-5229.126082.

10. de Silva HJ, Sanmuganathan PS, Senanayake N. Isolated bilateral recurrent laryngeal nerve paralysis: a delayed complication of organophosphorus poisoning. Hum Exp Toxicol 1994;13(3):171–173. DOI: 10.1177/096032719401300306.

11. Peter JV, Moran JL, Pichamuthu K, Chacko B. Adjuncts and alternatives to oxime therapy in organophosphate poisoning—Is there evidence of benefit in human poisoning? A review. Anaest Intensive Care 2008;36(3):339–350. DOI: 10.1077/0310057X0803600305.

12. Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet 2008;371(9612):597–607. DOI: 10.1016/S0140-6736(07)61202-1.

13. Peter JV, Moran JL, Graham P. Oxime therapy and outcomes in human organophosphate poisoning: an evaluation using meta-analytic techniques. Crit Care Med 2006;34(2):502–510. DOI: 10.1097/01.ccm.0000198325.46538.ad.

14. Li Y, Li H, Zhang D. Comparison of T-piece and pressure support ventilation as spontaneous breathing trials in critically ill patients: a systematic review and meta-analysis. Crit Care 2020;24(1):67. DOI: 10.1186/s13054-020-2764-3.

15. Donzelli J, Brady S, Wesling M, Theisen M. Secretions, occlusion status, and swallowing in patients with a tracheotomy tube: a descriptive study. Ear Nose Throat J 2006;85(12):831–834. PMID: 17240710.

16. Mota LAA, de Cavalho GB, Brito VA. Laryngeal complications by orotracheal intubation: literature review. Int Arch Otorhinolaryngol 2012;16(2):236–245. DOI: 10.18621/iaro.2012.2.236-245.

17. Norris BK, Schweinfurth JM. Arytenoid dislocation: an analysis of the contemporary literature. Laryngoscope 2011;121(1):142–146. DOI: 10.1002/lary.21276.

18. Lotti M, Moretto A. Organophosphate-induced delayed polyneuropathy. Toxicol Rev 2005;24:37–49. DOI: 10.2165/00139709-200524010-00003.

19. Wadia RS, Sadagopan C, Amin RB, Sardesai HV. Neurological manifestations of organophosphorous insecticide poisoning. J Neurol Neurosurg Psychiatry 1974;37(7):841–847. DOI: 10.1136/jnnp.37.7.841.

20. Sulica L. The superior laryngeal nerve: function and dysfunction. Otolaryngol Clin North Am 2004;37(1):183–201. DOI: 10.1016/S0030-6665(03)00175-0.

21. Périé S, Laccourreye O, Bou-Malhab F, Brasnu D. Aspiration in unilateral recurrent laryngeal nerve paralysis after surgery. Am J Otolaryngol 1998;19(1):18–23. DOI: 10.1016/s0196-0709(98)00060-6.

22. Benjamin B. Prolonged intubation injuries of the larynx: endoscopic diagnosis, classification, and treatment. Ann Otol Rhinol Laryngol 2018;127(8):492–507. DOI: 10.1177/0003489418790348.

23. Cooper JD. Tracheal injuries complicating prolonged intubation and tracheostomy. Thorac Surg Clin 2018;28(2):139–144. DOI: 10.1016/j.thorsur.2018.01.001.

24. Devaney KO, Rinaldo A, Ferlito A. Vocal process granuloma of the larynx—recognition, differential diagnosis and treatment. Oral Oncol 2005;41(7):666–669. DOI: 10.1016/j.oraloncology.2004.11.002.